Chronic wounds affect ~100m people around the world, impacting quality of life & placing a huge burden on health systems. Despite the many innovations in wound care over the years, chronic wound healing rates have barely improved. Change is needed – patients, practitioners, and regulators across the industry are in urgent need of high-impact innovations in chronic wound care.
SolasCure is at the forefront of addressing this demand, aiming to shift the current treatment
paradigm with a high impact therapeutic approach to debridement, with the goal of enabling dramatic improvements in healing rates and patients’ quality of life.
Aurase Wound Gel aims to address the huge unmet need for easy & effective debridement to return wounds to healing. It combines the enzyme Tarumase with hydrogel to debride wounds, reduce biofilm & promote healing. Tarumase is a highly-specific fibrinolytic enzyme cloned from maggot saliva, perfectly optimised by evolution for wound bed preparation.
After successful Phase IIa trials, SolasCure is preparing for the next phase of clinical development to bring Aurase Wound Gel one step closer to improving the lives of millions of patients suffering from chronic wounds.
For more information, you can find our peer-reviewed publications here:
Clinical: https://onlinelibrary.wiley.com/doi/10.1111/iwj.14805
Preclinical: https://onlinelibrary.wiley.com/doi/10.1111/iwj.14079
The importance of our innovative technology has been widely recognised:
- Innovate UK Global Incubator Programme (Innovate UK, the UK’s Innovation Agency), Texas Medical Center, 2024
- Biomedical Catalyst Grant (Innovate UK, the UK’s Innovation Agency), 2024
- EIC Accelerator Grant (European Innovation Council), 2023
- Life Sciences Innovator (UK Department for Trade and Business), 2023
- EIT Health Catapult, Biotech Category (European Institute of Innovation & Technology), 2022
- Winner 2019 URGO Mentorship Programme.
Visit us at www.solascure.com
